利伐沙班在急性冠脉综合征中的致死或不可逆出血与缺血事件
基于ATLAS ACS 2-TIMI 51试验,在接受阿司匹林联合氯吡格雷/噻氯匹定或单用阿司匹林治疗的ACS患者中,比较致死或不可逆缺血事件与致死或不可逆出血事件。利伐沙班2.5 mg每日两次可减少致死或不可逆缺血事件,每10,000患者年暴露净减少105例致死或不可逆事件。
要点
- 利伐沙班2.5 mg每日两次在阿司匹林联合氯吡格雷/噻氯匹定治疗患者中净减少致死或不可逆事件。
- 每10,000患者年暴露减少115例致死或不可逆缺血事件,增加10例致死或不可逆严重有害事件。
- 每预防1例致死或不可逆严重有害事件,可预防约11例致死或不可逆缺血事件。
核心结论
- 利伐沙班2.5 mg每日两次口服,在接受阿司匹林联合氯吡格雷/噻氯匹定治疗的ACS患者中,与致死或不可逆事件的净减少相关。
研究设计与样本
- ATLAS ACS 2-TIMI 51试验的事后分析,比较致死或不可逆缺血事件与致死或不可逆出血事件。
主要发现
- 利伐沙班2.5 mg每日两次组每10,000患者年暴露减少115例(95%CI:18至212)致死或不可逆缺血事件(安慰剂663例 vs 治疗548例)。
- 每10,000患者年暴露增加10例(95%CI:-11至32)致死或不可逆严重有害事件(33例 vs 安慰剂23例)。
- 净减少105例(95%CI:6至204)致死或不可逆事件每10,000患者年暴露。
- 每发生1例致死或不可逆严重有害事件,可预防11例(115例中10例)致死或不可逆缺血事件。
- 若仅将非出血性心血管死亡计入致死或不可逆事件,则每10,000患者年暴露预防95例事件。
临床怎么用
- 对于接受阿司匹林联合氯吡格雷/噻氯匹定治疗的ACS患者,可考虑利伐沙班2.5 mg每日两次以净减少致死或不可逆事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Net clinical outcome analyses of acute coronary syndrome (ACS) mingle fatal or irreversible events with survivable or reversible events that vary significantly in clinical impact. OBJECTIVES: A comparison of efficacy and safety limited to fatal or irreversible ischemic and adverse or seriously harmful events is one way to assess net clinical outcome and risk-benefit overall, given the fact that these events have a similar clinical impact. METHODS: In the ATLAS ACS 2-TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction) trial of rivaroxaban in the secondary prevention of events among patients with ACS treated with aspirin plus clopidogrel or ticlopidine (clopidogrel/ticlopidine) or aspirin alone, fatal and irreversible efficacy events including nonbleeding cardiovascular death, myocardial infarction, and ischemic stroke were compared to fatal or irreversible safety events, including fatal and intracranial bleeding. RESULTS: Rivaroxaban, 2.5 mg orally twice per day, in patients treated with aspirin and clopidogrel/ticlopidine was associated with 115 (95% confidence interval [CI]: 18 to 212) fewer fatal or irreversible ischemic events (663 for placebo vs. 548 for therapy) and 10 (95% CI: -11 to 32) additional fatal or irreversible seriously harmful events (33 vs. 23 for placebo) per 10,000 patient-years of exposure. Taken together, there would be 105 (95% CI: 6 to 204) fatal or irreversible events prevented per 10,000 patient-years of exposure to rivaroxaban compared with placebo, with 11 (10 of 115) fatal or irreversible ischemic events prevented for each fatal or irreversible seriously harmful event caused. If only nonbleeding cardiovascular death is included as a fatal or irreversible event, then 95 events would be prevented per 10,000 patient-years of exposure in the group taking 2.5 mg orally twice per day. CONCLUSIONS: Both fatal or irreversible ischemia and bleeding are clinically significant events that can be compared to assess the net clinical outcomes associated with therapy. Rivaroxaban therapy at an oral dose of 2.5 mg twice daily in patients treated with aspirin and clopidogrel is associated with a net reduction in fatal or irreversible events. (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction [ATLAS ACS 2-TIMI 51]; NCT00809965).
引用
- Gibson CM, Levitan B, Gibson WJ, et al. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. J Am Coll Cardiol. 2018. PMID: 29976285. doi:10.1016/j.jacc.2018.04.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。